ES2190093T3 - Uso de un producto proteico de neurturina para prevenir y tratar la perddida de audicion. - Google Patents

Uso de un producto proteico de neurturina para prevenir y tratar la perddida de audicion.

Info

Publication number
ES2190093T3
ES2190093T3 ES98937956T ES98937956T ES2190093T3 ES 2190093 T3 ES2190093 T3 ES 2190093T3 ES 98937956 T ES98937956 T ES 98937956T ES 98937956 T ES98937956 T ES 98937956T ES 2190093 T3 ES2190093 T3 ES 2190093T3
Authority
ES
Spain
Prior art keywords
protein product
hearing loss
neurturine
treat
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98937956T
Other languages
English (en)
Inventor
Ella Magal
John M Delaney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2190093T3 publication Critical patent/ES2190093T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Dairy Products (AREA)

Abstract

Una composición farmacéutica para prevenir y/o tratar la pérdida de audición sensorineuronal, o para tratar lesiones o alteraciones del aparato vestibular, que comprende un producto de proteína neurturina que tiene la secuencia de aminoácidos que aparece en la figura 4 (SEQ ID NO:3 y 4).
ES98937956T 1997-07-30 1998-07-17 Uso de un producto proteico de neurturina para prevenir y tratar la perddida de audicion. Expired - Lifetime ES2190093T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5418497P 1997-07-30 1997-07-30
US09/106,486 US6043221A (en) 1997-07-30 1998-06-29 Method for preventing and treating hearing loss using a neuturin protein product

Publications (1)

Publication Number Publication Date
ES2190093T3 true ES2190093T3 (es) 2003-07-16

Family

ID=26732740

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98937956T Expired - Lifetime ES2190093T3 (es) 1997-07-30 1998-07-17 Uso de un producto proteico de neurturina para prevenir y tratar la perddida de audicion.

Country Status (10)

Country Link
US (2) US6043221A (es)
EP (1) EP1005358B1 (es)
JP (1) JP2001525316A (es)
AT (1) ATE230607T1 (es)
AU (1) AU8658298A (es)
CA (1) CA2298414C (es)
DE (1) DE69810635T2 (es)
DK (1) DK1005358T3 (es)
ES (1) ES2190093T3 (es)
WO (1) WO1999006064A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
DE19807426A1 (de) * 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs
US6423321B2 (en) 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
WO2000073764A2 (en) 1999-06-01 2000-12-07 Baylor College Of Medicine Composition and methods for the therapeutic use of an atonal-associated sequence
US7053200B1 (en) 1999-06-01 2006-05-30 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
DE10025152A1 (de) * 2000-05-23 2001-12-06 Marlies Knipper Neurotrophin stimulierende Substanzen, insbesondere Thyroidhormon (T3) oder Schilddrüsenhormon stimulierende Substanzen, für die therapeutische Behandlung von lärm-und altersbedingter Schwerhörigkeit
US20050222070A1 (en) * 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
AUPR879201A0 (en) * 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
US20050171579A1 (en) * 2001-11-09 2005-08-04 Claudia Tasche Stimulating device
US20100030301A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Electrical stimulation for modulation of neural plasticity
US20100030130A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Pharmaceutical intervention for modulation of neural plasticity
AU2003208900A1 (en) * 2002-01-30 2003-09-02 House Ear Institute L-carnitine for treatment of hearing loss
EP1507553A2 (en) 2002-05-29 2005-02-23 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Pancreas-specific proteins
DE60335723D1 (de) * 2002-06-27 2011-02-24 Nippon Medical School Foundation Verfahren zum nachweis von perilymphatischen fisteln
US20040096089A1 (en) * 2002-08-16 2004-05-20 David Borsook Non-invasive functional imaging of peripheral nervous system activation in humans and animals
DE60332748D1 (de) * 2002-10-02 2010-07-08 Anges Mg Inc Arzneimittel gegen hörfunktionsstörungen
CA2549994A1 (en) 2002-12-18 2004-08-12 Hough Ear Institute Otologic nanotechnology
US7723311B2 (en) * 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
US8651113B2 (en) * 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
WO2005051415A1 (en) 2003-11-27 2005-06-09 Develogen Aktiengesellschaft Method for preventing and treating diabetes using neurturin
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
WO2005123140A2 (en) * 2004-06-08 2005-12-29 Alza Corporation Preparation of macromolecular conjugates by four-component condensation reaction
EP1765459B1 (en) 2004-06-15 2018-11-28 Cochlear Limited Automatic determination of the threshold of an evoked neural response
CN101137359B (zh) * 2005-03-10 2011-01-12 3M创新有限公司 治疗耳感染的方法
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
US9265933B2 (en) 2005-09-08 2016-02-23 Massachusetts Eye And Ear Infirmary Cochlear implants containing biological cells and uses thereof
EP1872790A1 (en) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
CA2742839A1 (en) * 2007-11-05 2009-05-14 Develogen Aktiengesellschaft Novel neurturin conjugates for pharmaceutical use
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
EP2278999A4 (en) 2008-04-21 2015-04-22 Otonomy Inc EARLY TREATMENT FORMULATIONS FOR THE TREATMENT OF EARLY DISEASES AND DRESSES
EP2493918A4 (en) * 2009-10-30 2013-04-10 Ntf Therapeutics Inc IMPROVED NEURTURINE MOLECULES
US20110195872A1 (en) * 2010-02-10 2011-08-11 Richard Selinfreund Devices and systems for biomarker detection
US20150359804A1 (en) * 2014-06-12 2015-12-17 Orbis Biosciences, Inc. Extended-release drug delivery compositions
FR3024361B1 (fr) * 2014-07-30 2017-11-24 Affichem Utilisation de derives de sterols pour traitement de la perte auditive neurosensorielle et composition correspondante
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
WO2020045980A1 (en) * 2018-08-28 2020-03-05 Industry-Academic Cooperation Foundation, Yonsei University Pharmaceutical composition for treating or preventing sensorineural hearing loss
CN110124014A (zh) * 2019-05-16 2019-08-16 杭州师范大学 重组人神经突起生长因子Neuritin蛋白的应用及一种用于治疗听神经病的药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
HU220795B1 (hu) * 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
DE69430824T2 (de) * 1993-08-12 2003-01-23 Neurotech Sa Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
AU1121997A (en) * 1995-11-29 1997-06-19 Amgen, Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product

Also Published As

Publication number Publication date
US6043221A (en) 2000-03-28
JP2001525316A (ja) 2001-12-11
ATE230607T1 (de) 2003-01-15
CA2298414C (en) 2004-09-28
DK1005358T3 (da) 2003-02-24
CA2298414A1 (en) 1999-02-11
DE69810635D1 (de) 2003-02-13
AU8658298A (en) 1999-02-22
WO1999006064A1 (en) 1999-02-11
DE69810635T2 (de) 2003-05-28
EP1005358A1 (en) 2000-06-07
EP1005358B1 (en) 2003-01-08
US6274554B1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
ES2190093T3 (es) Uso de un producto proteico de neurturina para prevenir y tratar la perddida de audicion.
IL121790A0 (en) Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor (GDNF) protein product
ATE277588T1 (de) Sprühbare zubereitungen enthaltend dispernierten pulvers sowie dessen anwendungsverfahren
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
EP1449834A3 (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
DE59410052D1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
ATE319712T1 (de) Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
CA2148988A1 (fr) Utilisation d'extraits de bacteries filamenteuses comme agents cosmetiques contre le vieillissement cutane
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
GB9504940D0 (en) Composition and method of preparing microemulsion blends
GB9425730D0 (en) Compounds
WO1999041364A3 (en) Compositions and methods for wound healing
WO1999060989A3 (de) Zubereitung zur behandlung der menschlichen haut und der menschlichen haare mit einer speziellen wirkstoffkombination sowie verwendung dieser wirkstoffkombination
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
EP0821969A3 (en) Medicinal Composition comprising TCF-II
WO2002004605A3 (en) Stimulation of cellular regeneration and differentiation in the inner ear
EP1304119A3 (en) Method for preventing and treating hearing loss using a neurturin protein product
ATE321772T1 (de) Echinocandinderivate, deren herstellung und deren verwendung zur bekämpfung von pilzen
ZA979135B (en) New cosmetic, dermopharmaceutical or veterinary compositions for the antiseptic treatment of human or animal skin.
IL91582A0 (en) Compositions for treating acne,for disinfecting the skin and the hair and for treating the hair
WO2001072955A3 (en) Regulation of human nedd1-related protein
WO2000061180A3 (en) Products and methods for treating ptp lar related diseases
EP0663211A4 (en) AGENT FOR PREVENTION AND TREATMENT OF DIGESTIVE APPARATUS MUCOUS DISORDERS.